by Fred Dumais | Sep 7, 2023 | News Release
MONTREAL, QUEBEC , September 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023...
by Fred Dumais | Aug 31, 2023 | Communiqué de presse
3,92 millions $ provenant d’un placement privé sans intermédiaire, et 0,58 million $ provenant d’un prêt d’un initié Investissement Québec et les initiés investissent chacun 2,0 millions $ Les produits du financement serviront à renforcer le fonds de...
by Fred Dumais | Aug 31, 2023 | News Release
$3.92 million raised from non-brokered private placement offering, and $0.58 million from insider loan Investissement Québec and insiders each invest $2.0 million Proceeds from the financing to be used to strengthen working capital and support ongoing growth...
by Fred Dumais | Jul 4, 2023 | Communiqué de presse
Novartis accepte de vendre à Bausch + Lomb les droits mondiaux de XIIDRA® et de plusieurs autres produits ophtalmologiques SIMBRINZA® n’est pas inclus dans la cession MONTRÉAL (QUÉBEC), le 4 juillet 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF,...
by Fred Dumais | Jul 4, 2023 | News Release
Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Bausch + Lomb SIMBRINZA® not included in the divestiture MONTREAL, QUEBEC, July 4, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE:VP2) (“Valeo” or the “Company”), a...
